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ABSTRACT
Objective: To explore the effects of microglial activation on brain function and structure, and its
relationship with peripheral inflammatory markers, in treated, HIV-positive individuals, using
in vivo [11C]PBR28 PET (to measure the 18 kDa translocator protein [TSPO]).
Methods: Cognitively healthy HIV-positive individuals on suppressive antiretroviral therapy and
HIV-negative individuals (controls) underwent brain [11C]PBR28 PET and MRI. HIV-positive pa-
tients completed neuropsychological testing and CSF testing for chemokines. The concentration
of bacterial ribosomal 16sDNA in plasma was measured as a marker of microbial translocation.
Results: HIV-positive individuals showed global increases in TSPO expression compared to con-
trols (corrected p , 0.01), with significant regional increases in the parietal (p 5 0.001) and
occipital (p 5 0.046) lobes and in the globus pallidus (p 5 0.035). TSPO binding in the hippo-
campus, amygdala, and thalamus were associated with poorer global cognitive performance in
tasks assessing verbal and visual memory (p , 0.05). Increased TSPO binding was associated
with increased brain white matter diffusion MRI mean diffusivity in HIV-positive individuals, a
lower CD4/CD8 ratio, and both high pretreatment HIV RNA and plasma concentration ribosomal
16s DNA (p , 0.05).
Conclusions: Cognitively healthy HIV-positive individuals show evidence for a chronically acti-
vated brain innate immune response and elevated blood markers of microbial translocation
despite effective control of plasma viremia. Increased brain inflammation is associated with
poorer cognitive performance and white matter microstructural pathology, suggesting a possible
role in cognitive impairments found in some HIV-positive patients despite effective treatment.
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GLOSSARY
cART 5 combination antiretroviral therapy; DTI 5 diffusion tensor imaging; DVR5 distribution volume ratio; FA 5 fractional
anisotropy; IL-85 interleukin-8; IP-105 interferon-g-inducible protein 10; LPS5 lipopolysaccharide;MD5mean diffusivity;
MIP-1b 5 macrophage inflammatory protein-1b; PLWH 5 people living with HIV; ROI 5 region of interest; SNP 5 single
nucleotide polymorphism; TSPO 5 translocator protein.
Despite improvements in life expectancy for people living with HIV (PLWH) after the advent of
combination antiretroviral therapy (cART),1 comorbidities including mild cognitive impair-
ment remain common.2,3 There is evidence that the inflammatory process following HIV
infection of the brain persists despite effective control of HIV RNA.4 Chronic activation of
brain microglia therefore has been suggested to be a major contributing factor for HIV-
associated brain disease.5,6
Translocator protein (TSPO) is highly expressed in the mitochondria of microglia and astro-
cytes.7 Following activation through host responses to cellular injury, microglia increase expres-
sion of TSPO.8 Increased binding of a TSPO radioligand therefore provides a proxy measure of
brain microglial activation that can be assessed in vivo with PET.
Previous studies investigating microglial activation using TSPO PET in PLWH have em-
ployed [11C]PK11195, a first-generation TSPO radioligand. The findings have been
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contradictory, with some studies demonstrat-
ing differences in [11C]PK11195 binding
between PLWH with and without cognitive
impairment9,10 and others showing no signifi-
cant differences between groups.11 Possible ex-
planations for these discrepancies could be
related to the difficulties in making accurate
measures of brain binding with this ligand
because of a lower proportion of the signal that
arises from specifically bound radioligand.12
[11C]PBR28 is a second-generation TSPO
radioligand with higher affinity for TSPO
and a high displaceable binding fraction.13,14
Unlike [11C]PK11195, the affinity for the tar-
get protein is determined by the rs6971 single
nucleotide polymorphism (SNP) in the TSPO
gene,15 and therefore incorporation of geno-
typic data enables an accurate quantitative
interpretation of TSPO PET data.16
The aim of this study was to test for
increased microglial activation in cognitively
healthy PLWH on effective cART. We also
tested for correlations between TSPO expres-
sion measured by PBR28 and markers of
peripheral immune activation, cognitive func-
tion, and brain structural MRI measures.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the National
Research Ethics Service (12/LO/1570). For the administration of
[11C]PBR28, permission was obtained from the UK Administra-
tion of Radioactive Substances Advisory Committee (630/3764/
29163). All participants provided informed consent prior to com-
mencing any study procedures.
Participant selection. HIV-positive cases. Twelve participants
were recruited from the HIV outpatient department at St. Mary’s
Hospital, Imperial College London, UK. Recruited PLWH were
men who had been HIV-1-antibody positive for at least 2 years
and were aged between 20 to 50 years and receiving stable cART
with a plasma HIV RNA of ,50 copies/mL at screening.
Exclusion criteria included any active neurologic or psychiatric
disease, current use of anti-inflammatories or benzodiazepines,
use of recreational drugs, or alcohol abuse.
HIV-negative controls. Historical data were available from
10 healthy HIV-negative participants between 20 to 60 years
old who had undergone the same [11C]PBR28 PET scanning
protocol and diffusion tensor imaging (DTI). Exclusion criteria
were identical to those of the HIV-positive cases. All control
participants provided written consent.
TSPO genotype. Blood samples were obtained from HIV-
positive participants and controls to determine the TSPO affin-
ity genotype. All participants were genotyped for the rs6971 SNP.
Only participants homozygous for the threonine rs6971 allele
(low affinity binders) were excluded from the study.
Cognitive testing. Cognitive testing was performed only in the
HIV-positive group using CogState (CogState Ltd., Melbourne,
Australia), a computerized battery previously validated in
PLWH.17 A total of 8 cognitive domains were assessed (speed,
visual attention, accuracy, visual learning, working memory,
verbal learning, associate learning, and executive function).
Overall scores from each task and composite Z scores were
calculated for each participant and compared against age-
matched normative population data (n 5 879) provided by the
manufacturer.
Biomarkers. Ribosomal 16sDNA. The concentration of bacte-
rial DNA encoding the ribosomal 16s rRNA in plasma was mea-
sured by quantitative real-time PCR in all HIV-positive
participants as previously described.18
CSF biomarkers. HIV-positive patients underwent a single
lumbar puncture. CSF HIV RNA concentration was measured
using the COBAS AmpliPrep v2.1 (Roche, Basel, Switzerland)
with a threshold of ,50 copies/mL. CSF concentrations of eo-
taxin, macrophage inflammatory protein-1b (MIP-1b),
interleukin-8 (IL-8), and interferon-g-inducible protein 10 (IP-
10) were investigated using the human chemokine cytokine assay
(Meso Scale Discovery, Gaithersburg, MD). Chemokine con-
centrations were assessed in blood and CSF samples and were
determined with Meso Scale Discovery Workbench software.
The lower limit of detection in both plasma and CSF chemo-
kines/cytokines (pg/mL) were eotaxin (8.3), MIP-1b (7.5), and
IL-8 (0.6).
Brain imaging. Volumetric imaging and DTI. High-resolu-
tion T1 and T2 magnetic resonance images and DTI were ob-
tained to determine the anatomical boundaries for volumetric
analysis and to assess the effects of inflammation on white matter
microstructure, respectively. Details of the MRI protocol are
described in the e-Methods on the Neurology® Web site at
Neurology.org.
[11C]PBR28 PET CT imaging. Details on radioligand syn-
thesis and PET protocol are described in the e-Methods. Each
participant was injected with an IV bolus of 400 MBq of [11C]
PBR28 over 20 seconds at the start of a 90-minute 3D mode
dynamic PET acquisition. PET data were reconstructed using
filtered back-projection with corrections for attenuation and
scatter.
Imaging data analysis. [11C]PBR28 PET CT. Dynamic PET
data were corrected for motion via frame-to-frame image regis-
tration and aligned with the individual’s structural T1 MRI using
SPM5 (Wellcome Trust Center for Neuroimaging; http://www.
fil.ion.ucl.ac.uk/spm). The CIC neuroanatomical atlas19 was
nonlinearly deformed into the individual’s space, via T1 MRI
data mapping, to obtain a personalized anatomical parcellation of
regions of interest. Attention focused on 20 regions of moderate
and high binding based on previous literature.20 Each region of
interest (ROI) was then applied to the dynamic PET data to
derive regional time-activity curves.
A 2-tissue compartment model, utilizing the metabolite-
corrected plasma input function, was applied to the dynamic
PET data using a fixed blood volume correction of 5%. For each
ROI examined, the total volume of distribution (VT) was esti-
mated from the rate constants as described previously by Gunn
et al.21 The Logan graphical method employing a plasma input,
5% fixed blood volume, and a linear start time at 35 minutes was
also used to estimate the absolute VT of each ROI and further
applied at the voxel level to produce a parametric VT map for each
participant. The main outcome measure is the total VT for each
defined brain region and a parametric VT map for each partici-
pant. The VT for a radioligand is defined as the ratio of concen-
tration in tissue to that in plasma at equilibrium (i.e., it is a
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partition coefficient) and is proportional to the level of specific
radioligand binding to TSPO. The distribution volume ratio
(DVR) in each ROI was also estimated by normalizing the VT to
cortical gray matter in order to evaluate local regional differences.
Normalization can control for unknown physiologic factors (unre-
lated to inflammation) that may affect radioligand brain uptake in
TSPO PET imaging studies.22 The gray matter was selected as an
area of control for normalization because of its relatively uniform
pattern of low baseline binding in healthy participants. Model fit-
ting and parameter estimation was performed using Matlab
R2008b (The MathWorks Inc., Natick, MA).
DTI. Standard DTI preprocessing methods were employed
using the FMRIB software library.23 DTI parameter maps were
generated using FMRIB’s Diffusion Toolbox in FSL for fractional
anisotropy (FA) and mean diffusivity (MD). The FA and MD
output images were used as input for tract-based spatial statistics.
A mean FA skeleton was created representing the centers of all
tracts common to the group. Mean FA and MD in major white
matter tracts for the HIV-positive participants were calculated by
projecting each individual skeleton through masks for the major
white matter tracts contained within the JHU white-matter
tractography atlas, alongside additional cortico-thalamic and
trans-collosal tracts defined by tractography.24
Statistical analysis. Differences in [11C]PBR28 binding between
HIV-positive participants and controls were studied both on ROI
level using analysis of variance with TSPO affinity phenotype effect
as a fixed factor using SPSS (SPSS, version 21, IBM, Armonk, NY)
and parametrically using the FSL Randomise tool accounting for
affinity status. Partial correlations were performed to investigate the
relationships between PBR28 binding and clinical, cognitive,
and MRI parameters including DTI adjusting for TSPO affinity
phenotype. Multiple comparisons were corrected by bootstrapping
for all measures.25 Associations between ribosomal 16sDNA and
PBR28 binding were also calculated using partial correlation
analysis adjusted for TSPO affinity status. Corrected p values
below 0.05 were considered statistically significant. Independent t
tests were used to contrast FA and MD between HIV-positive
participants and controls.
RESULTS Baseline characteristics and cognitive test
results. Patient demographics and clinical parameters
for HIV-positive participants are presented in
table 1. No significant differences were observed in
overall composite Z scores in HIV-positive
participants relative to the normative population
provided by the CogState manufacturer (p . 0.05,
all observations; see table e-1).
TSPO binding in HIV-positive individuals compared to
controls. In HIV-positive individuals, a global
increase in total [11C]PBR28 VT was observed
when compared to HIV-negative controls in a
parametric analysis (figure e-1). The global
increase in [11C]PBR28 VT was observed in both
high (C/C rs6971 alleles) and mixed (C/T rs6971
alleles) affinity binders. After normalization to
cortical gray matter, these increases in [11C]
PBR28 DVR in the HIV-positive participants (for
both the high and mixed affinity genotypes) were
found in the parietal (p5 0.001) and occipital (p5
0.046) lobes and in the globus pallidus (p 5 0.035)
(table 2) (figure e-2).
After adjusting for TSPO affinity genotype, a cor-
relation between increased [11C]PBR28 DVR and
lower CD4/CD8 ratio was found for the basal ganglia
(p, 0.005, r520.555), amygdala (p, 0.005, r5
20.759), hippocampus (p , 0.005, r 5 20.596),
and thalamus (p# 0.005, r520.525). Associations
between greater pretreatment HIV RNA and [11C]
PBR28 DVR in the occipital lobe (p , 0.005, r 5
0.684), parietal lobe (p, 0.005, r5 0.662), caudate
(p , 0.005, r 5 0.600), and striatum (p , 0.005,
r 5 0.604) were observed. Significant associations
between other HIV clinical parameters and [11C]
PBR28 DVR including nadir CD4 count, age, type
of cART, years of known duration of HIV infection,
Table 1 HIV-infected participant demographics and clinical parameters
Demographic/clinical characteristics HIV-infected HIV-negative controls
No. 12 10
Male, n (%) 12 (100) 10
Age, y, mean (SD) 42 (6.4) 41 (8.5)
TSPO genotype, n (%)
High affinity binders 8 (66) 6 (60)
Mixed affinity binders 4 (34) 4 (40)
Ethnicity, n (%)
White 10 (83.3) 10 (100)
Black 2 (16.7)
Education, y, mean (SD) 12 (2.5)
Current CD4/CD8 ratio 0.7 (0.2–0.9)
Current CD4 cell count, cells/mL 645 (350–1,240)
Nadir CD4 cell count, cells/mL 190 (70–350)
Baseline plasma HIV RNA level
<50 copies/mL, n (%)
12 (100)
Pretreatment HIV RNA copy years,
log 10 copies/mL
5.0 (2.1–6.2)
Time elapsed since HIV diagnosis, y 15 (2–19)
Time elapsed since starting cART, y 4 (2–16)
Antiretroviral therapy, n (%) 12 (100)
PI-based, n (%) 4 (33)
DRV/r 1
DRV/r, TDF, FTC 2
LOP/r, TDF, FTC 1
NNRTI-based, n (%) 8 (77)
NVP, TDF, FTC 4
NVP, ABC, 3TC 1
EFV, TDF, FTC 2
RLP, TDF, FTC 1
Abbreviations: 3TC 5 lamivudine; ABC 5 abacavir; cART 5 combination antiretroviral ther-
apy; DRV5 darunavir; EFV 5 efavirenz; FTC5 emtricitabine; LOP 5 lopinavir; NNRTI5 non-
nucleoside reverse transcriptase inhibitor; NVP 5 nevirapine; PI 5 protease inhibitor;
r 5 ritonavir; RLP 5 rilpivirine; TDF 5 tenofovir; TSPO 5 translocator protein.
Values are median (range) unless noted otherwise.
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and years since starting cART were not found (p .
0.1, all observations).
TSPO binding and neurocognitive performance. After
adjusting for TSPO affinity genotype and education,
greater [11C]PBR28 DVR in the hippocampus, amyg-
dala, and thalamus all were associated with poorer cog-
nitive global performance in HIV-positive individuals
(table 3). The strongest relationships were observed
between [11C]PBR28 DVR in the hippocampus and
thalamus and tests of memory (r520.624, p, 0.05)
and verbal learning (r 5 20.650, p , 0.05).
TSPO binding and white matter structure. Significantly
reduced brain white matter FA and increased MD
were observed in HIV-positive when compared
with HIV-negative controls in the splenius of the
corpus callosum, forceps major, corticospinal, and
cingulum hippocampus white matter tracts (tables
e-2 and e-3). After adjusting for TSPO genotype,
significant correlations between increased [11C]
PBR28 binding and MD values across most brain
white matter tracks were observed in the PLWH
group (table e-4). No significant correlations were
found between [11C]PBR28 binding and FA values
in any of the white matter tracts investigated (p .
0.10, all observations).
TSPO binding and biomarkers. CSF biomarkers.CSF was
obtained from 10/12 HIV-positive participants re-
cruited (the other 2 participants declined the proce-
dure). All individuals had CSF HIV RNA ,50
copies/mL. Mean eotaxin, MIP-1b, and IL-8 CSF
concentrations were 12.9 pg/mL (SD 5 11), 146.2
pg/mL (SD 5 18), and 2.8 pg/mL (SD 5 4.6),
respectively. CSF concentrations of IP-10 were below
the limit of detection for the assay. No associations
between TSPO binding and any of the CSF chemo-
kines were observed (p . 0.1, all observations).
Plasma r16S DNA. Plasma mean r16S DNA was
10.9 copies/mL in the HIV-positive group range
(SD5 14.2). An association between greater concen-
tration of ribosomal 16s DNA in plasma and
increased [11C]PBR28 DVR was observed in brain
regions with significant microglial activation such as
the basal ganglia and the globus pallidus (table 4). We
observed a significant association between plasma
Table 2 Regional [11C] PBR28 VT(DVR) in HIV-infected participants and controls
Brain region
HIV HABs Control HABs HIV MABs Control MABs
F Mean square Significance (p value)Mean SD Mean SD Mean SD Mean SD
Frontal lobe 1.01 0.02 0.99 0.04 0.97 0.02 0.99 0.01 1.88 0.002 0.187
Parietal lobe 0.99 0.02 0.96 0.02 0.94 0.02 1.00 0.01 27.99 0.010 0.001a
Occipital lobe 1.29 0.09 1.38 0.11 1.35 0.14 1.24 0.10 4.78 0.055 0.046a
Cingulate ctx 1.06 0.02 1.07 0.05 1.01 0.06 1.02 0.01 0.00 0.000 0.983
Insular ctx 1.08 0.04 1.08 0.05 1.03 0.13 1.06 0.08 0.35 0.002 0.562
Temporal lobe 0.97 0.02 1.05 0.05 1.06 0.02 0.98 0.02 22.02 0.033 0.001a
Hippocampus 1.06 0.07 1.10 0.11 1.07 0.11 1.04 0.08 0.63 0.006 0.439
Amygdala 1.13 0.07 1.20 0.18 1.12 0.16 1.08 0.05 0.79 0.015 0.386
Subcortical 1.07 0.06 1.04 0.08 1.00 0.12 1.04 0.02 0.93 0.006 0.348
Thalamus 1.21 0.07 1.20 0.11 1.08 0.15 1.15 0.03 0.96 0.010 0.341
Basal ganglia 0.97 0.05 0.91 0.07 0.96 0.11 0.94 0.03 0.36 0.002 0.557
Striatum 0.96 0.05 0.91 0.07 0.96 0.12 0.94 0.03 0.23 0.001 0.636
Putamen 1.04 0.03 0.97 0.09 1.02 0.08 1.02 0.06 1.34 0.006 0.263
Caudate 0.80 0.14 0.80 0.09 0.82 0.23 0.82 0.08 0.00 0.000 0.960
Globus pallidus 1.24 0.09 1.04 0.20 0.95 0.06 1.04 0.04 5.22 0.102 0.035a
Cerebellum 1.02 0.03 1.01 0.05 1.03 0.03 0.96 0.04 3.67 0.006 0.071a
Brainstem 1.28 0.13 1.27 0.15 1.19 0.07 1.18 0.11 0.00 0.000 0.971
Midbrain 1.03 0.03 0.97 0.04 1.05 0.04 1.04 0.03 1.75 0.002 0.203
Pons 1.30 0.19 1.29 0.17 1.12 0.10 1.17 0.12 0.14 0.004 0.715
Medulla 1.25 0.24 1.12 0.20 1.18 0.09 1.20 0.20 0.71 0.029 0.409
White matter 0.95 0.03 0.95 0.05 0.99 0.03 0.94 0.02 1.80 0.003 0.196
Abbreviations: ctx 5 cortex; HAB 5 high-affinity binders; MAB 5 mixed-affinity binders.
Results of factorial analysis of variance using genotype as a fixed factor.
a Significant.
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concentration of ribosomal 16s DNA and greater
MD values in the right inferior longitudinal fasciculus
(r5 0.601; p5 0.07), and an association trend in the
forceps major (r5 0.532; p5 0.07) and right inferior
fronto-occipital fasciculus (r5 0.509; p5 0.09) (fig-
ure e-3).
DISCUSSION The main goal of this study was to
assess the possible role of microglial activation in
PLWH on cART. We observed increased brain TSPO
radioligand uptake in vivo in HIV-positive individuals
on effective ART using [11C]PBR28 PET, suggesting
microglia (and, possibly, astroglial activation).12 In
contrast to some previous reports on TSPO
radioligand uptake9,11 in cognitively healthy PLWH,
we found evidence for widespread increases in brain
TSPO radioligand uptake. Regions of greatest TSPO
uptake, and, by inference, greatest neuroinflammation,
were found in subcortical brain gray matter,
particularly in the basal ganglia (globus pallidus,
caudate, and striatum). Markers of increased glial
activation and neuronal injury in subcortical brain
regions have been demonstrated previously by us
using proton magnetic resonance spectroscopy,
which has shown pathologically elevated myo-
inositol and choline and reduced NAA brain
metabolites in the basal ganglia in treated HIV-
positive participants26,27 in conjunction with elevated
markers of immune activation.28
Increased TSPO binding was associated with
poorer cognitive performance on cognitive tasks eval-
uating verbal learning and memory. Subcortical-
frontal white matter microstructural pathology has
been associated previously with impaired perfor-
mance on verbal learning29 and memory30 tests and
symptoms of poor attention, problem-solving diffi-
culties, and information retention and recall31 in
Table 3 Correlation coefficients (r) between [11C]PBR28 VT(DVR) and composite neurocognitive Z scores
adjusted for TSPO affinity status and education years
Region
Composite
speed
Composite accuracy
and visual learning
Composite memory
and verbal learning
Composite
executive function
Global cognitive
score
Occipital lobe 0.072 20.602a 0.145 0.301 0.390
Temporal lobe 0.382 0.67 0.253 0.329 0.114
Frontal lobe 0.391 0.148 0.161 0.330 0.070
Cingulate 0.380 0.045 0.188 0.298 0.065
Basal ganglia 0.394 0.111 0.138 0.255 0.103
Striatum 0.418 0.117 0.155 0.249 0.124
Caudate 20.236 0.252 0.017 0.131 20.208
Left putamen 0.075 0.658a 0.130 0.247 20.135
Globus pallidus 0.156 0.181 0.326 0.181 0.144
Hippocampus 20.771a 20.175 20.624a 20.156 20.624a
Hippocampus 20.771a 20.175 20.624a 20.156 20.624a
Right amygdala 20.750a 0.403 20.636a 0.210 20.635a
Thalamus 20.609a 0.250 20.650a 20.023 20.651a
Midbrain 20.689a 0.275 20.518 0.408 20.528b
Medulla 20.749a 0.133 20.672a 0.139 20.672a
White matter 20.665a 0.248 20.681a 20.200 20.681a
Results of correlation analyses corrected for multiple comparisons between [11C]PBR28 VT(DVR) and neurocognitive testing
Z scores, results adjusted for translocator protein status; 55 correlation coefficients were calculated (11 brain regions
multiplied by 5 cognitive composite domains).
ap , 0.05.
bp , 0.1.
Table 4 Correlation coefficients (r) between
[11C]PBR28 binding and plasma
concentration of ribosomal 16s DNA
adjusted for translocator protein
affinity status
Brain regions with increased
[11C]PBR28 VT(DVR)
Correlation
coefficient (r) p Value
Basal ganglia 0.881 0.002
Globus pallidus 0.928 0.001
Temporal lobe 0.818 0.003
Parietal lobe 0.832 0.002
Occipital lobe 0.861 0.023
Caudate 0.877 0.027
Striatum 0.811 0.001
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PLWH. With our evidence for substantial innate
immune activation, we speculate that the relation-
ships we observed between regions with TSPO radi-
oligand uptake and increased MD in white matter
may reflect increased inflammation.32
Although the cohort of PLWH we recruited did
not have cognitive symptoms, our results showing as-
sociations with cognitive test performance suggest a
possible link between neuroinflammation and their
subsequent development. However, the clinical mean-
ingfulness of the association between increases in
TSPO radioligand uptake in subcortical brain regions
and poorer cognitive performance is uncertain, as the
HIV-positive cases by definition were within normal
limits of cognitive function. Further studies are needed
to assess whether these are markers of risk for future
cognitive impairment. The anatomical distribution
implied by the correlations also needs further work
to confirm; we have not tested directly for differences
between regions in participants and the independence
of relationships between cognitive performance meas-
ures. As an exploratory characterization, the study also
may lack power to adequately test correlations such as
between basal ganglia TSPO radioligand uptake and
performance in cognitive domains such as composite
speed and executive function.
We found increased TSPO radioligand uptake was
associated with a lower CD4/CD8 ratio and increased
pretreatment HIV RNA. In virally suppressed
PLWH, a lower current CD4/CD8 ratio has been
associated with immune activation33 and cognitive
impairments.34 We hypothesize that the association
between lower CD4/CD8 ratio and greater TSPO
expression in the brain that we have observed reflects
a causal relationship among peripheral immune acti-
vation, breakdown of the blood–brain barrier, and
subsequent brain immune activation, possibly by facil-
itating HIV entry into the CNS early during infection.
Finally, we observed a significant association
between plasma concentration of ribosomal
16SDNA, a marker of microbial translocation, and
increased TSPO expression. The plasma concentra-
tion of ribosomal 16S DNA also correlated with
increased MD of white matter tracts. Microbial trans-
location from the gastrointestinal tract has been
strongly associated with persistent immune activation
in PLWH35 and HAD.36 An increase in PET [11C]
PBR28 uptake and a marker of microbial transloca-
tion in a nonhuman primate brain model was
observed after IV administration of Escherichia coli
lipopolysaccharide (LPS), a microbial product with
potent immune stimulatory activity. The underlying
microglial activation was correlated with increased
inflammatory cytokine levels, suggesting mediation
by LPS-induced inflammatory cytokines such as IL-
6 and IL-1b.37 More recently, [11C]PBR28 PET
evidence for microglial activation was reported for
humans following administration of LPS.38 We found
a significant association between plasma ribosomal
16SDNA and levels of the inflammatory chemokine
IL-8, which is consistent with the hypothesis that the
effects of microbial translocation on microglial acti-
vation are mediated by circulating inflammatory
chemokines.
This study describes a direct association between
in vivo microglial activation and microbial transloca-
tion in cognitively healthy PLWH stable on cART.
These results suggest a model whereby microglial acti-
vation in HIV-positive individuals is driven in part by
systemic inflammatory responses, which are, in turn,
triggered by the translocation of microbial products
across the impaired gut–blood barrier. This model is
consistent with immune activation–mediated injury
via nonspecific activation39 rather than direct damage
of HIV infection per se in the CNS compartment.
Our study has several limitations. First, the small
sample size and the stringent inclusion criteria limit
the generalizability of the results. However, the
robustness and convergence of independent observa-
tions (using PET and magnetic resonance) strongly
demonstrate the associations under at least some con-
ditions. Our study also is not longitudinal, so we can-
not test the causal relationships proposed. Second,
because of the small number of participants in each
group by genotype, we decided to adjust statistically
by genotype status using factorial analysis of variance
rather than comparing the groups directly. The lack
of significant associations between TSPO expression
and CSF biomarkers may be due to the selection of
chemokines measured in this study and limitations
of study power rather than absence of any relationship
between parenchymal and CSF inflammatory pro-
files. Nonetheless, the lack of correlation suggests that
independent information is provided by the PET and
CSF cytokine measures, possibly consistent with data
showing an influence of the inflammatory phenotype
of the choroid plexus, as well as parenchyma, on sol-
uble CSF inflammatory markers.40
Microglial activation has been proposed as a path-
ogenic mechanism in HIV-associated brain disease.
Our data suggest that in vivo microglial activation is
present in individuals with chronic HIV infection
on effective cART, without any cognitive or neuro-
logic deficit, and that microglial activation is associ-
ated with white microstructural changes and poor
performance on some cognitive tests. We also identi-
fied a correlation between biomarkers of microbial
translocation and microglial activation, which we
hypothesize may be mediated by the expression of
inflammatory chemokines. Therefore, our findings
suggest a link between peripheral inflammation and
microglial activation in treated HIV-positive patients.
6 Neurology 86 April 12, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Longitudinal studies are needed to assess whether
increased [11C]PBR28 PET signal (or other markers
of neuroinflammation) are markers of risk for pro-
gression from asymptomatic, mild impairments of
cognitive performance to symptomatic cognitive
impairment.
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